Matthew E Peters1, Vijay Vaidya2, Lea T Drye2, Davangere P Devanand3, Jacobo E Mintzer4, Bruce G Pollock5, Anton P Porsteinsson6, Paul B Rosenberg1, Lon S Schneider7, David M Shade2, Daniel Weintraub8, Jerome Yesavage9, Constantine G Lyketsos10, Dimitri Avramopoulos1. 1. Johns Hopkins University School of Medicine, Baltimore, MD, USA. 2. Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 3. Columbia University Medical Center, New York, NY, USA. 4. Medical University of South Carolina, Charleston, SC, USA. 5. Centre for Addiction and Mental Health, Campbell Family Institute, Toronto, Canada University of Toronto, Toronto, Canada. 6. University of Rochester School of Medicine, Rochester, NY, USA. 7. Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA. 8. University of Pennsylvania School of Medicine, Philadelphia, PA, USA. 9. Stanford University School of Medicine, Stanford, CA, USA. 10. Johns Hopkins University School of Medicine, Baltimore, MD, USA kostas@jhmi.edu.
Abstract
OBJECTIVE: To assess potential genetic influences on citalopram treatment efficacy for agitation in individuals with Alzheimer dementia (AD). Six functional genetic variants were studied in the following genes: serotonin receptor 2A (HTR2A-T102C), serotonin receptor 2C (HTR2C-Cys23Ser), serotonin transporter (5HTT-LPR), brain-derived neurotropic factor (BDNF-Val66Met), apolipoprotein E (ε2, ε3, ε4 variants), and cytochrome P450 (CYP2C19). Treatment response by genotype was measured by (1) the agitation domain of the Neurobehavioral Rating Scale, (2) the modified Alzheimer Disease Cooperative Study-Clinical Global Impression of Change scale (mADCS-CGIC), (3) the agitation domain of the Neuropsychiatric Inventory (NPI), and (4) the Cohen-Mansfield Agitation Inventory. METHOD: We utilized data from the Citalopram for Agitation in Alzheimer's Disease (CitAD) database. CitAD was a 9-week randomized, double-blind, placebo-controlled multicenter clinical trial showing significant improvement in agitation and caregiver distress in patients treated withcitalopram. Proportional odds logistic regression and mixed effects models were used to examine the above-mentioned outcome measures. RESULTS: Significant interactions were noted on the NPI agitation domain for HTR2A (likelihood ratio [LR] = 6.19, df = 2, P = .04) and the mADCS-CGIC for HTR2C (LR = 4.33, df = 2, P = .02) over 9 weeks. DISCUSSION: Treatment outcomes in CitAD showed modest, although statistically significant, influence of genetic variation at HTR2A and HTR2C loci. Future studies should continue to examine the interaction of known genetic variants with antidepressant treatment in patients with AD having agitation.
RCT Entities:
OBJECTIVE: To assess potential genetic influences on citalopram treatment efficacy for agitation in individuals with Alzheimer dementia (AD). Six functional genetic variants were studied in the following genes: serotonin receptor 2A (HTR2A-T102C), serotonin receptor 2C (HTR2C-Cys23Ser), serotonin transporter (5HTT-LPR), brain-derived neurotropic factor (BDNF-Val66Met), apolipoprotein E (ε2, ε3, ε4 variants), and cytochrome P450 (CYP2C19). Treatment response by genotype was measured by (1) the agitation domain of the Neurobehavioral Rating Scale, (2) the modified Alzheimer Disease Cooperative Study-Clinical Global Impression of Change scale (mADCS-CGIC), (3) the agitation domain of the Neuropsychiatric Inventory (NPI), and (4) the Cohen-Mansfield Agitation Inventory. METHOD: We utilized data from the Citalopram for Agitation in Alzheimer's Disease (CitAD) database. CitAD was a 9-week randomized, double-blind, placebo-controlled multicenter clinical trial showing significant improvement in agitation and caregiver distress in patients treated with citalopram. Proportional odds logistic regression and mixed effects models were used to examine the above-mentioned outcome measures. RESULTS: Significant interactions were noted on the NPI agitation domain for HTR2A (likelihood ratio [LR] = 6.19, df = 2, P = .04) and the mADCS-CGIC for HTR2C (LR = 4.33, df = 2, P = .02) over 9 weeks. DISCUSSION: Treatment outcomes in CitAD showed modest, although statistically significant, influence of genetic variation at HTR2A and HTR2C loci. Future studies should continue to examine the interaction of known genetic variants with antidepressant treatment in patients with AD having agitation.
Authors: L Kathryn Durham; Suzin M Webb; Patrice M Milos; Cathryn M Clary; Albert B Seymour Journal: Psychopharmacology (Berl) Date: 2003-09-04 Impact factor: 4.530
Authors: Pauline Aalten; Marjolein E de Vugt; Niek Jaspers; Jaspers Jolles; Frans R J Verhey Journal: Int J Geriatr Psychiatry Date: 2005-06 Impact factor: 3.485
Authors: Dimitrios S Christidis; Evangelos N Liberopoulos; Anna I Kakafika; George A Miltiadous; Marios Cariolou; Emmanuel S Ganotakis; Dimitri P Mikhailidis; Moses S Elisaf Journal: J Cardiovasc Pharmacol Ther Date: 2006-09 Impact factor: 2.457
Authors: H S Levin; W M High; K E Goethe; R A Sisson; J E Overall; H M Rhoades; H M Eisenberg; Z Kalisky; H E Gary Journal: J Neurol Neurosurg Psychiatry Date: 1987-02 Impact factor: 10.154
Authors: R H Myers; E J Schaefer; P W Wilson; R D'Agostino; J M Ordovas; A Espino; R Au; R F White; J E Knoefel; J L Cobb; K A McNulty; A Beiser; P A Wolf Journal: Neurology Date: 1996-03 Impact factor: 9.910
Authors: Clive Ballard; Helen C Kales; Constantine Lyketsos; Dag Aarsland; Byron Creese; Roger Mills; Hilde Williams; Robert A Sweet Journal: Curr Neurol Neurosci Rep Date: 2020-10-13 Impact factor: 5.081